$200M investment to advance clinical programs for Ambrx
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
The company is working to move its CD47-targeting drug, ALX148, into Phase II development. Another company, Forty Seven, is also developing a CD47-targeting therapy. CD47 is an immune checkpoint distinct from the ones targeted by currently marketed cancer immunotherapy drugs.
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
The company expects the funding to bring it into the clinic and is also in partnering talks with academic institutions and biopharma companies, said co-founder Jonathan Lim, who previously led Ignyta.
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.
The startup created from Dana-Farber Cancer Institute announced today the closing of a $73 million Series A round of financing and a promising partnership with Roche.